New Cystic Fibrosis Drug Eases Breathing

Friday, 19 Apr 2013 12:27 PM


  Comment  |
   Contact Us  |
|  A   A  
  Copy Shortlink
Vertex Pharmaceuticals Inc said its experimental drug improved lung function in adults with cystic fibrosis in a mid-stage trial, sending its shares 54 percent higher in after-hours trading.
The company said on Thursday the favorable results were seen in patients who took the drug, known as VX-661, in combination with its already approved treatment for cystic fibrosis, Kalydeco (ivacaftor) in a short 28-day study.
The Phase II study involved 128 people with cystic fibrosis who had two copies of the most common gene mutation responsible for the debilitating condition in which the lungs are unable to flush out salt and therefore become flooded with mucous and can become easily infected.
Patients treated in the two highest dose groups had a mean relative increase in lung function of between 7.5 percent and 9 percent, compared with patients given a placebo.
The results were "impressive," Wells Fargo analyst Brian Abrahams said in a research note.

He added that they "meaningfully increase the likelihood of success" for the company's program to develop combination treatments for cystic fibrosis.
He has estimated the market for a dual cystic fibrosis treatment at over $3 billion.
Vertex said the experimental drug was generally well tolerated when used alone and in combination with Kalydeco.

© 2014 Thomson/Reuters. All rights reserved.

  Comment  |
   Contact Us  |
  Copy Shortlink
Around the Web
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
Retype Email:
Zip Code:
Find Your Condition
You May Also Like
Around the Web
Most Commented

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, NewsmaxWorld, NewsmaxHealth, are trademarks of Newsmax Media, Inc.

© Newsmax Media, Inc.
All Rights Reserved